(38), the radiolabeled Copper-64-p-SCN-Bn-PCTA-cetuximab (64Cu-PCTA-cetuximab) was employed to target EGFR in HNSCC models. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.